Our mission

The MiDe Study (MicroRNA Detection Study) is working to develop a diagnostic test for ovarian cancer early detection. Join us in our effort to understand this rare cancer better.

MiDe Study Principal Investigators (PIs) Dr. Dipanjan Chowdhury and Dr. Kevin Elias have discovered a set of novel (new) molecules, called microRNAs (miRNAs), that are found in the blood and may predict ovarian cancer. Currently, there are no screening or early detection tests available for ovarian cancer. In early studies, MiDe’s new test has shown very promising results in the detection of ovarian cancer in otherwise healthy people.

In collaboration with Dr. Judy Garber, the MiDe Study opened in the fall of 2019 to determine the accuracy of this test in detecting ovarian cancer in high-risk people.

Our goals

The MiDe Study aims to:

  • Better understand ovarian cancer risk for people at high risk (including people with a genetic link to cancer and family history of cancer)
  • Improve cancer prevention, early detection, and treatment strategies for people at high risk for ovarian cancer
  • Determine the accuracy (validate) a new early ovarian cancer detection test using microRNAs found in a blood sample

Participating in the MiDe Study

By joining the MiDe Study, you can make a difference by helping us to better understand how ovarian cancer develops in high-risk people. Please join our effort to better understand this rare cancer.


Adults over the age of 18 with at least one ovary intact and no personal history of ovarian cancer are invited to join the MiDe Study. If you are unsure if you may be eligible, please contact the study team. Additionally, eligible adults may:

  • Have a genetic variant(s) linked to ovarian cancer on genetic testing, such as BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, PALB2, or EPCAM
  • Have a blood relative who carries a genetic variant found on genetic testing
  • Have a family history of cancer, such as breast, ovarian, or gastrointestinal (GI) cancer(s)

Participating in the MiDe Study means that you’ll:

  • Review and sign a consent form
  • Complete a family history questionnaire and provide updates on your personal and family history periodically throughout your time in the study
  • Allow us to access your medical records for information that may be important to your participation in the study
  • Provide up to 4 tubes of blood every 6 months for up to 5 years
  • Allow us to collect some of your biopsy or surgery tissue samples for research, if possible